CRISPR Therapeutics Faces Stagnant Stock Despite Promising Pipeline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: Fool
- Therapeutic Impact: CRISPR Therapeutics' gene-editing therapy Casgevy was approved in 2023, and despite a steep price of $2.2 million per patient, over 500 patients have begun treatment, indicating initial market acceptance; however, the high cost remains a significant barrier to broader adoption.
- Strong Financial Position: With a market cap of $5.5 billion and over $2.4 billion in liquidity, the consensus analyst price target of $80.62 is 40% above the current stock price, yet the stock has stagnated since 2022, reflecting concerns about future profitability.
- Complex Treatment Process: The Casgevy therapy requires personalized customization using patients' own blood stem cells, making the treatment process complex and time-consuming, which delays revenue recognition and pressures short-term financial performance.
- Financing and Dilution Risks: The company issued $600 million in convertible notes in March, potentially diluting the existing 96.5 million shares, which, while common in biotech financing, raises investor concerns about future profitability and share value stability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 60.080
Low
50.00
Averages
78.89
High
105.00
Current: 60.080
Low
50.00
Averages
78.89
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Comparative Investment in Gene Editing and Metabolic Medicine
- CRISPR's Market Position: CRISPR Therapeutics leads in gene editing, recently achieving its first product approval for rare blood disorders, yet its fiscal 2025 revenue of $3.5 million reflects a nearly 90% decline from the previous year, highlighting risks associated with its reliance on partnership-driven revenue.
- Viking's Clinical Challenges: Viking Therapeutics focuses on therapies for metabolic and endocrine disorders, reporting no revenue in fiscal 2025 and a net loss of approximately $359.6 million, indicating high risks associated with its clinical pipeline investments and dependence on Ligand Pharmaceuticals' licensing agreement, which could jeopardize drug development.
- Financial Health Comparison: CRISPR's current ratio stands at 13.3, indicating strong short-term solvency, but its free cash flow of negative $345.9 million underscores ongoing financial losses; conversely, Viking's current ratio of 9.3 and zero debt suggest a healthier financial structure, albeit with significant operational losses.
- Investment Outlook Assessment: While CRISPR's high valuation with a forward P/E of 19.1 contrasts with Viking's 17.7, both companies exhibit substantial growth potential in the biotech market, yet CRISPR's minimal sales, despite being small, render it more appealing to investors compared to Viking's pre-revenue status.
See More
Investment Outlook for CRISPR and Viking Therapeutics
- CRISPR Financial Challenges: CRISPR Therapeutics reported approximately $3.5 million in revenue for fiscal 2025, a nearly 90% decline year-over-year, with a net loss of about $581.6 million, highlighting the volatility of biotech revenues and increasing financial sustainability risks due to reliance on its partnership with Vertex Pharmaceuticals.
- Viking Clinical Investments: Viking Therapeutics reported no revenue for fiscal 2025, with a net loss of approximately $359.6 million as it heavily invests in its clinical pipeline for obesity and metabolic diseases; despite its zero-debt financial status, it faces uncertainties regarding regulatory approvals.
- Market Competition Analysis: CRISPR leads in gene editing with a high valuation but has achieved a breakthrough treatment for sickle cell disease, while Viking remains in the clinical stage without revenue, presenting higher investment risks.
- Investor Considerations: While both companies operate in high-growth sectors, CRISPR's sales performance makes it more attractive to investors, whereas Viking's prospects depend on its licensing agreement with Ligand Pharmaceuticals, where any changes could significantly impact its drug development timeline.
See More
FDA Expands Approval for Casgevy Gene Therapy to Younger Patients
- Expanded Indication: The FDA's approval of Casgevy now allows its use in children as young as two years old, significantly increasing the eligibility of approximately 5,500 additional children in the U.S., marking the first application of this therapy in the pediatric population and expected to greatly enhance Crispr's market potential.
- Increased Commercial Opportunity: Crispr benefits from a 40% share of net profits from Casgevy under its collaboration with Vertex, and this expansion directly increases the potential revenue pool for Crispr, strengthening its competitive position in the gene therapy market.
- Positive Market Reaction: Following the FDA approval, Crispr's stock surged 8%, reflecting investor optimism about the company's future growth, while Vertex's shares also rose 6%, indicating market recognition of its product line expansion.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around Crispr shifted from 'neutral' to 'bullish', with message volume significantly increasing, suggesting growing confidence in Crispr's future performance, which may drive further stock price appreciation.
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: The ARKK ETF has a 52-week low of $62.945 and a high of $92.65, with the last trade at $82.55, indicating significant volatility and shifts in investor sentiment within the market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in the assessment of market trends and potential buy or sell opportunities.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the fund.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, as these liquidity shifts can significantly affect the performance of the underlying stocks held within the ETFs.
See More
Investment Comparison Between CRISPR and Vertex
- CRISPR's Financial Challenges: CRISPR Therapeutics AG reported revenue of only $3.5 million for FY 2025, a staggering 90% decline year-over-year, reflecting significant challenges in its commercialization process, with a net loss of approximately $581.6 million indicating heavy investment needs for its clinical pipeline.
- Vertex's Profitability: Vertex Pharmaceuticals generated nearly $12 billion in revenue for FY 2025, an 8.9% year-over-year increase, with a net income of about $4 billion and a net margin of 32.7%, showcasing its mature business model and stable cash inflows.
- Risk Comparison: CRISPR faces substantial financial sustainability risks, including frequent capital raises and intellectual property litigation, while Vertex relies heavily on sales from its cystic fibrosis drugs, making it vulnerable to new competition and regulatory risks.
- Valuation Differences: CRISPR has a forward P/E ratio of 18.6x but an astronomical P/S ratio of 1270x, whereas Vertex's forward P/E is 25.3x with a P/S ratio of 10x, highlighting significant differences in market valuations between the two companies.
See More
Investment Comparison: CRISPR vs. Vertex Pharmaceuticals
- CRISPR Financial Struggles: CRISPR Therapeutics AG reported nearly $3.5 million in revenue for FY 2025, a staggering 90% decline year-over-year, primarily due to transitions in milestone recognition and commercial rollout, resulting in a net loss of approximately $581.6 million, highlighting the heavy investment burden on its clinical pipeline.
- Vertex Profitability: Vertex Pharmaceuticals generated close to $12 billion in revenue for FY 2025, reflecting an 8.9% year-over-year increase, with a net income of approximately $4.0 billion and a net margin of 32.7%, indicating a mature business model with steady cash inflows.
- Partnership Risks and Patent Litigation: CRISPR faces significant risks in its partnership with Vertex, including a patent infringement lawsuit from ToolGen, and any disruption in this relationship could materially harm its commercial prospects and long-term viability.
- Divergent Investor Mindsets: Investors must weigh their risk tolerance when choosing between CRISPR and Vertex, as CRISPR represents a high-risk, high-reward gene-editing technology, while Vertex offers a stable cash-generating business suitable for those seeking patient investments.
See More
Comparative Investment in Gene Editing and Metabolic Medicine
- CRISPR's Market Position: CRISPR Therapeutics leads in gene editing, recently achieving its first product approval for rare blood disorders, yet its fiscal 2025 revenue of $3.5 million reflects a nearly 90% decline from the previous year, highlighting risks associated with its reliance on partnership-driven revenue.
- Viking's Clinical Challenges: Viking Therapeutics focuses on therapies for metabolic and endocrine disorders, reporting no revenue in fiscal 2025 and a net loss of approximately $359.6 million, indicating high risks associated with its clinical pipeline investments and dependence on Ligand Pharmaceuticals' licensing agreement, which could jeopardize drug development.
- Financial Health Comparison: CRISPR's current ratio stands at 13.3, indicating strong short-term solvency, but its free cash flow of negative $345.9 million underscores ongoing financial losses; conversely, Viking's current ratio of 9.3 and zero debt suggest a healthier financial structure, albeit with significant operational losses.
- Investment Outlook Assessment: While CRISPR's high valuation with a forward P/E of 19.1 contrasts with Viking's 17.7, both companies exhibit substantial growth potential in the biotech market, yet CRISPR's minimal sales, despite being small, render it more appealing to investors compared to Viking's pre-revenue status.
See More
Investment Outlook for CRISPR and Viking Therapeutics
- CRISPR Financial Challenges: CRISPR Therapeutics reported approximately $3.5 million in revenue for fiscal 2025, a nearly 90% decline year-over-year, with a net loss of about $581.6 million, highlighting the volatility of biotech revenues and increasing financial sustainability risks due to reliance on its partnership with Vertex Pharmaceuticals.
- Viking Clinical Investments: Viking Therapeutics reported no revenue for fiscal 2025, with a net loss of approximately $359.6 million as it heavily invests in its clinical pipeline for obesity and metabolic diseases; despite its zero-debt financial status, it faces uncertainties regarding regulatory approvals.
- Market Competition Analysis: CRISPR leads in gene editing with a high valuation but has achieved a breakthrough treatment for sickle cell disease, while Viking remains in the clinical stage without revenue, presenting higher investment risks.
- Investor Considerations: While both companies operate in high-growth sectors, CRISPR's sales performance makes it more attractive to investors, whereas Viking's prospects depend on its licensing agreement with Ligand Pharmaceuticals, where any changes could significantly impact its drug development timeline.
See More
FDA Expands Approval for Casgevy Gene Therapy to Younger Patients
- Expanded Indication: The FDA's approval of Casgevy now allows its use in children as young as two years old, significantly increasing the eligibility of approximately 5,500 additional children in the U.S., marking the first application of this therapy in the pediatric population and expected to greatly enhance Crispr's market potential.
- Increased Commercial Opportunity: Crispr benefits from a 40% share of net profits from Casgevy under its collaboration with Vertex, and this expansion directly increases the potential revenue pool for Crispr, strengthening its competitive position in the gene therapy market.
- Positive Market Reaction: Following the FDA approval, Crispr's stock surged 8%, reflecting investor optimism about the company's future growth, while Vertex's shares also rose 6%, indicating market recognition of its product line expansion.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around Crispr shifted from 'neutral' to 'bullish', with message volume significantly increasing, suggesting growing confidence in Crispr's future performance, which may drive further stock price appreciation.
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: The ARKK ETF has a 52-week low of $62.945 and a high of $92.65, with the last trade at $82.55, indicating significant volatility and shifts in investor sentiment within the market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in the assessment of market trends and potential buy or sell opportunities.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the fund.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, as these liquidity shifts can significantly affect the performance of the underlying stocks held within the ETFs.
See More
Investment Comparison Between CRISPR and Vertex
- CRISPR's Financial Challenges: CRISPR Therapeutics AG reported revenue of only $3.5 million for FY 2025, a staggering 90% decline year-over-year, reflecting significant challenges in its commercialization process, with a net loss of approximately $581.6 million indicating heavy investment needs for its clinical pipeline.
- Vertex's Profitability: Vertex Pharmaceuticals generated nearly $12 billion in revenue for FY 2025, an 8.9% year-over-year increase, with a net income of about $4 billion and a net margin of 32.7%, showcasing its mature business model and stable cash inflows.
- Risk Comparison: CRISPR faces substantial financial sustainability risks, including frequent capital raises and intellectual property litigation, while Vertex relies heavily on sales from its cystic fibrosis drugs, making it vulnerable to new competition and regulatory risks.
- Valuation Differences: CRISPR has a forward P/E ratio of 18.6x but an astronomical P/S ratio of 1270x, whereas Vertex's forward P/E is 25.3x with a P/S ratio of 10x, highlighting significant differences in market valuations between the two companies.
See More
Investment Comparison: CRISPR vs. Vertex Pharmaceuticals
- CRISPR Financial Struggles: CRISPR Therapeutics AG reported nearly $3.5 million in revenue for FY 2025, a staggering 90% decline year-over-year, primarily due to transitions in milestone recognition and commercial rollout, resulting in a net loss of approximately $581.6 million, highlighting the heavy investment burden on its clinical pipeline.
- Vertex Profitability: Vertex Pharmaceuticals generated close to $12 billion in revenue for FY 2025, reflecting an 8.9% year-over-year increase, with a net income of approximately $4.0 billion and a net margin of 32.7%, indicating a mature business model with steady cash inflows.
- Partnership Risks and Patent Litigation: CRISPR faces significant risks in its partnership with Vertex, including a patent infringement lawsuit from ToolGen, and any disruption in this relationship could materially harm its commercial prospects and long-term viability.
- Divergent Investor Mindsets: Investors must weigh their risk tolerance when choosing between CRISPR and Vertex, as CRISPR represents a high-risk, high-reward gene-editing technology, while Vertex offers a stable cash-generating business suitable for those seeking patient investments.
See More
